Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada

American Journal Geriatric Pharmacotherapy

Volumn 2, Issue 3, 2004, Pages 171-180

  Hartnell, Nicole R ^a   Flanagan, Priti S ^b   MacKinnon, Neil J ^a   Bakowsky, Volodko S ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b FRASER HEALTH AUTHORITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

COX 2 selective inhibitors; Gastrointestinal complications; Gastrointestinal risk factor; Geriatric pharmacotherapy; Nonsteroidal anti inflammatory drugs; Prescribing

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; CELECOXIB; CIMETIDINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; RANITIDINE; ROFECOXIB; WARFARIN;

AGED; ARTHRITIS; ARTICLE; CANADA; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; DRUG USE; DRUG UTILIZATION; ELDERLY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ANTIRHEUMATIC AGENTS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; NOVA SCOTIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 10244243670     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2004.09.001     Document Type: Article

References (29)

1. IMS HEALTH COX-2 inhibitors increase size of antiarthritic market by 35% Available at: Http://www.imshealthcanada.com. Accessed October 23, 2002
2. IMS Health Snapshots on disease: Arthritis Academic Reference Manual 2001 IMS Health Pointe-Claire, QC 72
3. Smalley W.E. Ray W.A. Daugherty J.R. Griffin M.R. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons Am Epidemiol 141 1995 539-545
4. Silverstein E.E. Graham D.Y. Senior J.R. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 241-249
5. Hawkey C.J. Langman M.J. Non-steroidal anti-inflammatory drugs: Overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors Gut 52 2003 600-608
6. Hunt R.H. Barkun A.N. Baron D. et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents Can J Gastroenterol 16 2002 231-240
7. Government publication National Institute of Clinical Excellence (NICE) Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis 2001 Technology Appraisal Guidance No. 27 London
8. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 Update Arthritis Rheum 46 2002 328-346
9. Tannenbaum H. Peloso P.M. Russell A.S. Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference Can J Clin Pharmacol 7 (Suppl A) 2000 4A-16A
10. Lame L. Gastrointestinal effects of NSAIDs and coxibs J Pain Symptom Manage 25 Suppl 2 2003 S32-S40
11. Weil J. Langman M.J. Wainwright P. et al. Peptic ulcer bleeding: Accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs Gut 46 2000 27-31
12. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs Am J Cardiol 89 Suppl 6A 2002 3D-9D
13. Gabriel S.E. Jaakkimaincn L. Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. A meta-analysis Ann Intern Med 115 1991 787-796
14. Bombardier C. Lame L. Reicin A. et al. VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520-1528
15. Silverstein F.E. Faich G. Goldstein J.L. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: The Class Study: A randomized controlled trial. Celecoxib Long-term Safety Study JAMA 284 2000 1247-1255
16. Taha A.S. Hudson N. Hawkcy C. et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs N Engl J Med 334 1996 1435-1439
17. Rostom A. Dube C. Wells G. et al. Prevention of NSAID-associated gastroduodenal ulcers (Cochrane Review) The Cochrane Library Issue 2 2003
18. Graham D.Y. Agrawal N.M. Campbell D.R. et al. NSAID-Associated Gastric Ulcer Prevention Study Group Ulcer prevention in long-term users of nonstcroidal antiinflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole Arch Intern Med 162 2002 169-175
19. Chan F.K. Hung L.C. Sucn B.Y. et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis N Engl J Med 347 2002 2104-2110
20. Bakowsky V.S. Hanly J.G. Complications of nonsteroidal antiinflammatory gastropathy and use of gastric cytoprotection: Experience at a tertiary care health center J Rheumatal 26 1999 1557-1563
21. Visser L.E. Graatsma H.H. Stricker B.H. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease Br J Clin Pharmacol 53 2002 183-188
22. Smalley W. Stein C.M. Arbogast P.G. et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal anti-inflammatory drugs Arthritis Rheum 46 2002 2195-2200
23. Tamblyn R. Berkson L. Dauphince W.D. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice Ann Intern Med 127 1997 429-438
24. Baumann A.O. Deber R.B. Thompson G.G. Overconfidence among physicians and nurses: The 'microcertainty, macro-uncertainty' phenomenon Soc Sci Med 32 1991 167-174
25. Comparative costs of 30 days supply of drugs for OA February 2002 Dalhousie University Continuing Medical Education Available at: http://www.mcdicinc.dal.ca/cmc/OA.pdf. Accessed April 7, 2003
26. Maetzel A. Krahn M. Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis Technology report no. 23 2001 Canadian Coordinating Office for Health Technology Assessment Ottawa
27. Redelmeier D.A. Tan S.H. Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases N Engl J Med 338 1998 1516-1520
28. Tamblyn R. Laprise R. Hanley J.A. et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons JAMA 285 2001 421-429
29. Soumerai S.B. Ross-Degnan D. Avorn J. et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes N Engl J Med 325 1991 1072-1077